Reuters logo
3 个月前
BRIEF-Minerva announces amended agreement for MIN-202 in insomnia
2017年5月31日 / 晚上8点44分 / 3 个月前

BRIEF-Minerva announces amended agreement for MIN-202 in insomnia

May 31 (Reuters) - Minerva Neurosciences Inc

* Minerva announces amended agreement for MIN-202 in insomnia

* Janssen cash payments to Minerva of up to $70 million, including $30 million upfront

* Minerva phase 2 development payments totaling $13 million to be waived

* All shares in co held by an affiliate of Janssen to be repurchased at par value

* ‍under amended agreement, Minerva will gain global strategic control of development of MIN-202 to treat insomnia​

* ‍Will retain its current rights to MIN-202 as adjunctive therapy for major depressive disorder​

* Amendment and stock repurchase are conditional upon closing of pending acquisition of Actelion Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below